CA2653657C - Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor - Google Patents

Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor Download PDF

Info

Publication number
CA2653657C
CA2653657C CA2653657A CA2653657A CA2653657C CA 2653657 C CA2653657 C CA 2653657C CA 2653657 A CA2653657 A CA 2653657A CA 2653657 A CA2653657 A CA 2653657A CA 2653657 C CA2653657 C CA 2653657C
Authority
CA
Canada
Prior art keywords
methyl
phenyl
propenamide
hydroxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2653657A
Other languages
English (en)
French (fr)
Other versions
CA2653657A1 (en
Inventor
Murat Acemoglu
Joginder S. Bajwa
David John Parker
Joel Slade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Secura Bio Inc
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2653657(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2653657A1 publication Critical patent/CA2653657A1/en
Application granted granted Critical
Publication of CA2653657C publication Critical patent/CA2653657C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2653657A 2006-06-12 2007-06-07 Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor Active CA2653657C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80452706P 2006-06-12 2006-06-12
US60/804,527 2006-06-12
US86787806P 2006-11-30 2006-11-30
US60/867,878 2006-11-30
PCT/US2007/070564 WO2007146718A2 (en) 2006-06-12 2007-06-07 Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino] methyl]phenyl]-2e-2-propenamide and starting materials therefor

Publications (2)

Publication Number Publication Date
CA2653657A1 CA2653657A1 (en) 2007-12-21
CA2653657C true CA2653657C (en) 2015-10-27

Family

ID=38832681

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2653657A Active CA2653657C (en) 2006-06-12 2007-06-07 Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor

Country Status (31)

Country Link
US (2) US20090306405A1 (enExample)
EP (2) EP2032533B8 (enExample)
JP (2) JP5431926B2 (enExample)
KR (2) KR101493530B1 (enExample)
CN (4) CN102167678B (enExample)
AR (1) AR061296A1 (enExample)
AU (1) AU2007257883B2 (enExample)
BR (1) BRPI0712847A2 (enExample)
CA (1) CA2653657C (enExample)
CL (2) CL2007001691A1 (enExample)
DK (1) DK2032533T3 (enExample)
EC (1) ECSP088978A (enExample)
ES (2) ES2553255T3 (enExample)
GT (1) GT200800282A (enExample)
HR (1) HRP20130798T1 (enExample)
IL (2) IL195211A (enExample)
IN (1) IN2015DN00910A (enExample)
JO (1) JO2900B1 (enExample)
MA (1) MA30513B1 (enExample)
MX (2) MX2008015898A (enExample)
MY (1) MY147576A (enExample)
NO (1) NO341870B1 (enExample)
NZ (1) NZ572707A (enExample)
PE (2) PE20120221A1 (enExample)
PL (1) PL2032533T3 (enExample)
PT (1) PT2032533E (enExample)
RU (1) RU2448090C2 (enExample)
TN (1) TNSN08507A1 (enExample)
TW (1) TWI395734B (enExample)
WO (1) WO2007146718A2 (enExample)
ZA (1) ZA200809490B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000004075A1 (it) 2020-02-27 2021-08-27 Flamma Spa Processo per la preparazione di panobinostat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146260A (en) 1918-07-11 1921-08-11 Elektro Osmose Ag A process for preparing proteids charged with immune substances
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002237261A1 (en) 2001-01-09 2002-07-24 Novartis Pharma Gmbh Rapid method for screening compounds for in vivo activity
NZ544689A (en) 2001-11-06 2007-08-31 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
AU2007257882B2 (en) * 2006-06-12 2011-09-08 Secura Bio Inc. Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide

Also Published As

Publication number Publication date
CN103086944A (zh) 2013-05-08
EP2394991A1 (en) 2011-12-14
PL2032533T3 (pl) 2013-08-30
JP5809223B2 (ja) 2015-11-10
KR20140117703A (ko) 2014-10-07
JP5431926B2 (ja) 2014-03-05
HK1126759A1 (en) 2009-09-11
NO341870B1 (no) 2018-02-12
IL233836A0 (en) 2014-09-30
AU2007257883A1 (en) 2007-12-21
PE20120221A1 (es) 2012-03-21
NZ572707A (en) 2011-12-22
CN102167678B (zh) 2013-08-28
US8536346B2 (en) 2013-09-17
CL2010000973A1 (es) 2011-07-01
CN102174008A (zh) 2011-09-07
WO2007146718A2 (en) 2007-12-21
CN102167678A (zh) 2011-08-31
KR101540194B1 (ko) 2015-07-28
BRPI0712847A2 (pt) 2012-08-07
ES2553255T3 (es) 2015-12-07
TW200815345A (en) 2008-04-01
RU2008151726A (ru) 2010-07-20
KR101493530B1 (ko) 2015-02-13
MX2008015898A (es) 2009-01-12
HK1162029A1 (en) 2012-08-17
DK2032533T3 (da) 2013-07-01
WO2007146718A3 (en) 2008-06-19
ZA200809490B (en) 2009-10-28
HRP20130798T1 (en) 2013-09-30
RU2448090C2 (ru) 2012-04-20
JO2900B1 (en) 2015-09-15
EP2032533B1 (en) 2013-04-03
GT200800282A (es) 2009-03-09
ECSP088978A (es) 2009-01-30
PE20080851A1 (es) 2008-08-18
NO20090137L (no) 2009-03-03
ES2416286T3 (es) 2013-07-31
AR061296A1 (es) 2008-08-20
KR20090015969A (ko) 2009-02-12
US20090306405A1 (en) 2009-12-10
CN101466674A (zh) 2009-06-24
TNSN08507A1 (en) 2010-04-14
PT2032533E (pt) 2013-06-28
EP2394991B1 (en) 2015-09-23
US20120010418A1 (en) 2012-01-12
CA2653657A1 (en) 2007-12-21
MY147576A (en) 2012-12-31
JP2014058532A (ja) 2014-04-03
TWI395734B (zh) 2013-05-11
MX366213B (es) 2019-07-01
IL195211A (en) 2014-08-31
EP2032533B8 (en) 2013-12-11
IL195211A0 (en) 2009-08-03
CL2007001691A1 (es) 2008-05-16
IN2015DN00910A (enExample) 2015-07-10
MA30513B1 (fr) 2009-06-01
IL233836A (en) 2017-05-29
EP2032533A2 (en) 2009-03-11
JP2009540008A (ja) 2009-11-19
AU2007257883B2 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
CA3077888C (en) Indacaterol free base in solid form
CZ296895B6 (cs) Zpusob prípravy kyseliny (+-)-3-(aminomethyl)-5-methylhexanové
TW201708191A (zh) 用於製備前列腺素醯胺之新穎方法（二）
EP2032533B1 (en) Process for making n-hydroxy-3-ý4-ýýý2-(2-methyl-1h-indol-3-yl)ethyl¨amino¨methyl¨phenyl¨-2e-2-propenamide and starting materials therefor
JPH11292844A (ja) 光学的に活性なインドリン―２―カルボン酸またはその誘導体の製造法
HK1162029B (en) Process for making starting materials for n-hydroxy-3-[4-[2-(2-methyl-1 h-indol-3-yl)-ethylaminomethyl]-phenyl]-2e-2-propenamide
HK1126759B (en) Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor
JP7578670B2 (ja) 置換ピラゾール誘導体の調製方法
KR100859902B1 (ko) 4,5-다이아미노 망초산의 제조 방법
JPH04360866A (ja) ３−アミノピロリジン類の製造方法
JP2010530397A (ja) アミド形成の改善方法
HU213634B (en) Method for producing 5-chlorine-2,3-dihydro-2-oxo-indole
JP2002326978A (ja) ４−アミノシクロヘキシル酢酸またはそのエステルの製造法
JPH07267913A (ja) 置換フェニルヒドラゾンの製造方法

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251203

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260720